1. Scar-modulating agents post urethroplasty: Could phosphodiesterase-5 inhibitors be the answer?
- Author
-
Shady Emara and Ammar Alhasso
- Subjects
medicine.medical_specialty ,Anti fibrotic ,030219 obstetrics & reproductive medicine ,Urethral stricture ,business.industry ,Urology ,Urethroplasty ,medicine.medical_treatment ,030232 urology & nephrology ,Phosphodiesterase ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Erectile dysfunction ,cGMP-specific phosphodiesterase type 5 ,medicine ,Surgery ,business - Abstract
Background: Phosphodiesterase enzyme inhibitors (PDEIs) are most commonly prescribed by urologists for the treatment of erectile dysfunction. They are also gaining popularity as a treatment for lower urinary tract symptoms, based on their effect on smooth muscles – either vascular smooth muscles or smooth muscles in the urinary tract. For vascular smooth muscles, they cause vasodilation, enhanced microcirculatory haemodynamics through inhibition of platelet aggregation and adhesion, induction of apoptosis of adhesion fibroblasts and a reduction in the scarring process. Methodology: We reviewed articles published in English and indexed in the PubMed, Embase and Google Scholar databases, and consulted textbooks. Key search terms used were: urethral stricture, anti-fibrotic, scar-modulating agent, PDEIs, urethral scarring and urethroplasty. We created a synopsis of relevant articles, including original research studies and reviews. Level of evidence: Not applicable.
- Published
- 2020
- Full Text
- View/download PDF